Genomic Sequencing in Pediatric Cancer: For Every Patient at Every Relapse
More than one-third of tumors sequenced carried a high mutation burden.
More than one-third of tumors sequenced carried a high mutation burden.
Clinicians should have a standard approach for discussing the risk of adverse events associated with immune checkpoint inhibitors, researchers say.
Researchers provided recommendations for managing adverse events in patients with renal cell carcinoma receiving cabozantinib and nivolumab.
Researchers analyzed whole-genome sequencing data from 76,805 patients to identify variants in 4 genes that are associated with adverse reactions to capecitabine, fluorouracil, mercaptopurine, thioguanine,…
This cross-sectional study investigates if there are differences in the receipt of recurrence-focused treatment and overall survival in patients with pancreatic ductal adenocarcinoma recurrence who…
Most RCC patients surveyed said telemedicine visits are comparable to in-person visits, but most oncology providers disagreed.
An intervention reduced prior authorization delays or denials, the time needed for treatment plan completion, and the time until prior authorization was completed.
The combination of vidutolimod and nivolumab “stimulates a broad antitumor immune response,” according to researchers.
Metastectomy has a “high probability of success” in patients with RCC, according to researchers.
Enfortumab vedotin produced a response in 23.9% of patients.
“The addition of a PLK1 inhibitor to chemotherapy/bevacizumab exhibits very promising activity in patients with previously treated but bevacizumab-naive KRAS-mutant mCRC,” said Andrew H. Ko,…